Oncobiologics (NASDAQ:ONS) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday.
Shares of ONS stock traded down $0.01 during trading hours on Thursday, reaching $0.89. The stock had a trading volume of 11,449 shares, compared to its average volume of 8,747. Oncobiologics has a 12 month low of $0.77 and a 12 month high of $1.53.
Oncobiologics (NASDAQ:ONS) last announced its earnings results on Tuesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $0.77 million for the quarter.
Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha.
Read More: What Is An Exchange-Traded Fund (ETF)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.